• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-6 POS filed by DBV Technologies S.A.

    5/17/24 5:18:36 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DBVT alert in real time by email
    F-6 POS 1 e663621_f6pos-dbv.htm

     

    As filed with the Securities and Exchange Commission on May 17, 2024 Registration No. 333 - 266202

     

     

     

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-6

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY 

    AMERICAN DEPOSITARY RECEIPTS

     

     

     

    DBV TECHNOLOGIES S.A. 

    (Exact name of issuer of deposited securities as specified in its charter)

     

     

     

    N/A 

    (Translation of issuer’s name into English)

     

     

     

    Republic of France 

    (Jurisdiction of incorporation or organization of issuer)

     

     

     

     CITIBANK, N.A. 

    (Exact name of depositary as specified in its charter)

     

     

     

    388 Greenwich Street

    New York, New York 10013

    (877) 248-4237 

    (Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

     

     

     

    Michele Robertson

    DBV Technologies Inc.

    10 Independence Blvd.

    Suite 302

    Warren, New Jersey 07059

    +1 908-679-5200 

    (Address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

     

    Richard Segal

    Marc Recht

    Cooley LLP
    55 Hudson Yards

    New York, New York 10001

    +1 212 479 6000

     

    Arnaud Duhamel

    Guilhem Richard

    Gide Loyrette Nouel A.A.R.P.I.

    15 rue de Laborde

    75008 Paris France

    +33 1 40 75 00 00

     

    Herman H. Raspé, Esq.

    Patterson Belknap Webb & Tyler LLP
    1133 Avenue of the Americas
    New York, New York 10036
    (212) 336-2301

     

     

     

      It is proposed that this filing become effective under Rule 466: o   immediately upon filing.  
        o  on (Date) at (Time).

     

    If a separate registration statement has been filed to register the deposited shares, check the following box:  o

     

     

     

    The Registrant hereby amends this Post-Effective Amendment No. 1 to Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Post-Effective Amendment No. 1 to Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until this Post-Effective Amendment No. 1 to Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

    This Post-Effective Amendment No. 1 to Registration Statement on Form F-6 may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

     

    ii

     

     

     

    PART I

     

    INFORMATION REQUIRED IN PROSPECTUS

     

    Cross Reference Sheet

     

    Item 1.  DESCRIPTION OF SECURITIES TO BE REGISTERED

     

    Item Number and Caption  

    Location in Form of American

    Depositary Receipt (“Receipt”)

    Filed Herewith as Prospectus

           
    1.    Name of Depositary and address of its principal executive office   Face of Receipt -  Introductory Article.
             
    2. Title of Receipts and identity of deposited securities   Face of Receipt  - Top Center.
         
    Terms of Deposit:    
      (i)       The amount of deposited securities represented by one American Depositary Share ("ADSs")   Face of Receipt  - Upper right corner.
             
      (ii) The procedure for voting, if any, the deposited securities  

    Reverse of Receipt  - Paragraphs (16) and (17).

             
      (iii) The collection and distribution of dividends   Reverse of Receipt - Paragraph (14).
             
      (iv) The transmission of notices, reports and proxy soliciting material  

    Face of Receipt  - Paragraph (13);

    Reverse of Receipt - Paragraph (16).

             
      (v) The sale or exercise of rights  

    Reverse of Receipt – Paragraphs (14) and (16).

             
      (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization  

    Face of Receipt - Paragraphs (3) and (6);

    Reverse of Receipt - Paragraphs (14) and (18).

             
      (vii) Amendment, extension or termination of the deposit agreement   Reverse of Receipt - Paragraphs (22) and (23) (no provision for extensions).
             
      (viii) Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs   Face of Receipt - Paragraph (13).

     

    I-1

     

     

     

    Item Number and Caption  

    Location in Form of American

    Depositary Receipt (“Receipt”)

    Filed Herewith as Prospectus

             
      (ix)   Restrictions upon the right to deposit or withdraw the underlying securities   Face of Receipt – Paragraphs (2), (3), (4), (6), (7), (9) and (10).
             
      (x) Limitation upon the liability of the Depositary  

    Face of Receipt - Paragraph (7);

    Reverse of Receipt - Paragraphs (19) and (20).

             
    3. Fees and charges which may be imposed directly or indirectly on holders of ADSs   Face of Receipt - Paragraph (10).
           
    Item 2. AVAILABLE INFORMATION   Face of Receipt - Paragraph (13).

     

    The Company is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”).  These reports can be retrieved from the Commission’s internet website (www.sec.gov).

     

    I-2

     

     

     

    PROSPECTUS

     

    The Prospectus consists of the proposed form of American Depositary Receipt included as Exhibit A to the Form of Amendment No. 1 to Deposit Agreement filed as Exhibit (a)(i) to this Post-Effective Amendment No. 1 to the Registration Statement on Form F-6 and is incorporated herein by reference.

     

    I-3

     

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 3.EXHIBITS

     

    (a)(i) Form of Amendment No. 1 to Deposit Agreement, by and among DBV Technologies S.A. (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ___ Filed herewith as Exhibit (a)(i).

     

    (ii) Deposit Agreement, dated as of October 24, 2014, by and among the Company, the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (“Deposit Agreement”). ___ Previously filed as Exhibit (a) to the Registration Statement (Reg. No. 333-266202) with the Commission on July 18, 2022.

     

    (b)Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby. ___ None.

     

    (c)Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ___ None.

     

    (d)Opinion of counsel for the Depositary as to the legality of the securities to be registered. ___ None.

     

    (e)Certificate under Rule 466. ___ None.

     

    (f)Powers of Attorney for certain officers and directors and the authorized representative of the Company. ___ Set forth on the signature pages hereto.

     

    II-1

     

     

     

    Item 4.UNDERTAKINGS

     

    (a)The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

     

    (b)If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

     

    II-2

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, by and among DBV Technologies S.A., Citibank, N.A., as depositary, and all Holders and Beneficial Owners of American Depositary Shares to be issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 1 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 17th day of May, 2024.

     

      Legal entity created by the Deposit Agreement under which the American Depositary Shares registered hereunder are issued, each American Depositary Share representing the right to receive one (1) ordinary share of DBV Technologies S.A.
         
      CITIBANK, N.A., solely in its capacity as Depositary
         
      By:  /s/ Mark Gherzo
        Name:  Mark Gherzo
        Title:    Attorney-in-Fact

     

    II-3

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, DBV Technologies S.A. certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 1 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in Châtillon, France, on May 17, 2024.

     

      DBV Technologies S.A.
         
      By:   /s/ Virginie Boucinha
        Name:  Virginie Boucinha
        Title:    Chief Financial Officer

     

    II-4

     

     

     

    POWERS OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Daniel Tassé and Virginie Boucinha to act as his/her true and lawful attorney-in-fact and agent, with full power of substitution, for him/her and in his/her name, place and stead, in any and all such capacities, to sign any and all amendments, including post-effective amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as s/he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to Registration Statement on Form F-6 has been signed by the following persons in the following capacities on May 17, 2024.

     

    Signature   Title
         
    /s/ Daniel Tassé   Chief Executive Officer and Director
    Daniel Tassé   (Principal Executive Officer)
         
    /s/ Virginie Boucinha   Chief Financial Officer
    Virginie Boucinha   (Principal Financial and Accounting Officer)
       
    /s/ Michel de Rosen   Director
    Michel de Rosen    
         
    /s/ Maïlys Ferrère   Director
    Maïlys Ferrère    
         
    /s/ Michael J. Goller   Director
    Michael J. Goller    
         
    /s/ Daniele Guyot-Caparros   Director
    Daniele Guyot-Caparros    
         
    /s/ Timothy E. Morris   Director
    Timothy E. Morris  
         
    /s/ Adora Ndu   Director
    Adora Ndu    
         
    /s/ Julie O’Neill   Director
    Julie O’Neill    
         
    /s/ Ravi M. Rao   Director
    Ravi M. Rao    
         
    /s/ Daniel B. Soland    Director

    Daniel B. Soland 

       

     

    II-5

     

     

     

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF REGISTRANT

     

     Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of DBV Technologies S.A. has signed this registration statement on May 17, 2024.

     

      DBV Technologies Inc.
         
      By:   /s/ Michele Robertson
        Name:  Michele Robertson
        Title:    Chief Legal Officer, Vice President

     

    II-6

     

     

     

    Index to Exhibits

     

    Exhibit Document

    Sequentially

    Numbered Page

         
    (a)(i) Form of Amendment No. 1 to Deposit Agreement  
         
         
         
         
         
         

     

     

     

     

     

    Get the next $DBVT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DBVT

    DatePrice TargetRatingAnalyst
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    12/3/2025$35.00Buy
    Guggenheim
    5/29/2025$7.25Sell
    Goldman
    1/4/2023Hold → Buy
    Societe Generale
    12/16/2022Neutral → Sell
    Goldman
    5/10/2022$6.00 → $1.50Buy → Neutral
    Goldman
    12/21/2021$8.00 → $5.00Market Outperform
    JMP Securities
    12/21/2021$14.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on DBV Technologies with a new price target

    Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00

    12/15/25 9:59:53 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on DBV Technologies with a new price target

    Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00

    12/3/25 8:16:35 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman resumed coverage on DBV Technologies with a new price target

    Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25

    5/29/25 8:17:33 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit

    Châtillon, France, February 9, 2025 DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit which is being held February 11-12, 2026 in New York, NY. Mr. Tassé's presentation is scheduled for Thursday, February 12, at 2:30pm ET. A live webcast of the fireside chat can be accessed here and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/ev

    2/9/26 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

    Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights01/31/2026 274,852,082  Total gross of voting rights: 274,852,082  Total net* of voting rights: 274,792,237  * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

    2/5/26 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

    Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is sufficiently funded to support operations and commercial preparedness, including infrastructure buildup, to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if approved. DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced a supplementary financing of €166.7 Million (the "Exercise") resulting from the full exercise of (i) 34,090,004 warrants attached to new ordinary shares issued by the Company on April 7,

    1/16/26 6:11:29 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by DBV Technologies S.A.

    SCHEDULE 13G - DBV Technologies S.A. (0001613780) (Subject)

    2/3/26 2:00:02 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by DBV Technologies S.A.

    8-K - DBV Technologies S.A. (0001613780) (Filer)

    1/16/26 8:29:58 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by DBV Technologies S.A.

    SCHEDULE 13D/A - DBV Technologies S.A. (0001613780) (Subject)

    1/14/26 5:36:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Mohideen Pharis sold $2,595 worth of Ordinary Shares (534 units at $4.86), decreasing direct ownership by 0.37% to 144,995 units (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    2/2/26 4:30:20 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Baker Bros. Advisors Lp

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    1/14/26 4:33:18 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Member of 10% owner group Epic Bpifrance sold $15,484,143 worth of Ordinary Shares (3,369,093 units at $4.60) (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    12/19/25 4:04:06 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Tasse Daniel bought $14,188 worth of Ordinary Shares (17,094 units at $0.83) (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    3/11/24 4:15:38 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ndu Adora bought $1,624 worth of Ordinary Shares (1,825 units at $0.89) (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    2/8/24 5:02:03 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Financials

    Live finance-specific insights

    View All

    DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

    Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the placebo arm Safety results were consistent with the safety profile observed in the VIASKIN Peanut clinical program to dateBLA submission in 4-7-year-olds on track for the first half of 2026Achievement

    12/16/25 4:05:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

    Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc

    6/25/25 4:15:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

    Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE    DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FD

    1/8/25 4:05:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Leadership Updates

    Live Leadership Updates

    View All

    DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

    Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su

    11/3/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

    Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the "Board"), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company's shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company's Board comprises ten directors. "We are pleased

    10/30/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Resignation of Board Member

    Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the "Board"), effective immediately. "On behalf of the Board, DBV's management team and shareholders, I thank Daniel for his commitment to the Company," said Michel de Rosen, Chairman of the Board. "Since joining the Board in 2015, Daniel's experience, insights and expertise have been invaluable to the Board and its Compensation Committee. We wish him continued success in his future endeavors." "It has been a

    9/18/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    11/14/24 4:55:56 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    2/14/24 8:56:45 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    2/14/24 4:06:12 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care